Skip to main content

Table 4 Administration of radiochemotherapy

From: Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction

  Dose level  
  1 2 3 Total
Number of patients 4 (100%) 13 (100%) 7 (100%) 24 (100%)
Chemotherapy delay?     
  No 3 (75%) 5 (38%) 5 (71%) 13 (54%)
  Yes 1 (25%) 8 (62%) 2 (29%) 11 (46%)
If yes, reason for delay:     
  Administrative reason 1 (100%) 4 (50%) 1 (50%) 6 (55%)
  Adverse event   4 (50%) 1 (50%) 5 (45%)
Chemotherapy reduction?     
  No 3 (75%) 11 (85%) 6 (86%) 20 (83%)
  Yes 1 (25%) 2 (15%) 1 (14%) 4 (17%)
If so, reason for reduction:     
  Administrative reason   1 (50%)   1 (25%)
  Adverse event 1 (100%) 1 (50%) 1 (100%) 3 (75%)
Radiotherapy total dose (Gy)     
  Mean (SD) 46.8 (4.41) 44.45 (10.68) 46.54 (2.63) 45.45 (8.07)
  Median (range) 47.7 (41.4–50.4) 45.0 (10.8–50.4) 45.0 (45.0–50.4) 45.0 (10.8–50.4)